Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant

Villas-Boas, Lucy Santos; A, de Paula; Silva, Almir Ribeiro da; Paião, Heuder Gustavo Oliveira; Tozetto‐Mendoza, Tânia Regina; Manuli, Erika R.; Leal, Fábio E.; Ferraz, Andrea de Barros Coscelli; Sabino, Éster Cerdeira; Bierrenbach, Ana Luiza; Mendes-Corrêa, Maria Cássia

doi:10.1016/j.clinsp.2022.100068

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, it appears that the speci c antibodies generated against earlier SARS-CoV-2 variants did not cross-react with the Omicron variant (25). This suggests that the immune response generated by previous infections may not provide effective protection to cats against the Omicron variant.…”

Section: Full Textmentioning

confidence: 99%

No detection of SARS-CoV-2 in domestic cats exposed to infected owners during the Omicron Wave in São Paulo, Brazil

Lopes

Rigato

Kasinski

et al. 2023

Preprint

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been demonstrated to infect various mammals, including cats, dogs, and minks. Given the close coexistence of humans and cats, transmission of SARS-CoV-2 variants between these two species has been documented. This study involved the sampling of eight domestic cats that resided solely with their infected owners in Brazil, during the early stage of the Omicron variant wave. Nasal and anal secretion samples obtained from the eight cats were subjected to RT-qPCR analysis, which revealed no detection of SARS-CoV-2. Additionally, serum samples collected from these cats did not show the presence of anti-SARS-CoV-2 antibodies. The findings of this study indicate that the Omicron variant has a low potential to infect felines, which contributes to the absence of transmission. Therefore, cats do not appear to play a significant role in the transmission chain of SARS-CoV-2.

show abstract

Section: Full Textmentioning

confidence: 99%

No detection of SARS-CoV-2 in domestic cats exposed to infected owners during the Omicron Wave in São Paulo, Brazil

Lopes

Rigato

Kasinski

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Vilibic-Cavlek,

Stevanovic,

Kovac

et al. 2023

Antibodies

View full text Add to dashboard Cite

Background: Serological diagnosis of COVID-19 is complex due to the emergence of different SARS-CoV-2 variants. Methods: 164 serum samples from (I) patients who recovered from COVID-19 (n = 62) as well as (II) vaccinated individuals (n = 52) and (III) vaccinated individuals who were infected with different SARS-CoV-2 variants after vaccination (n = 50) were included. All samples were tested using EIA (binding antibodies) and a virus neutralization test (VNT) using the Wuhan strain (NT antibodies). Group III was further tested with a VNT using the Alpha/Delta/Omicron strains. Results: The highest antibody index (AI) was observed in vaccinated individuals infected with COVID-19 (median AI = 50, IQR = 27–71) and the lowest in vaccinated individuals (median AI = 19, IQR = 8–48). Similarly, NT antibody titer was highest in vaccinated individuals infected with COVID-19 (median 128; IQR = 32–256) compared to vaccinated individuals (median 32, IQR = 4–128) and patients with COVID-19 (median 32, IQR = 8–64). The correlation between AI and NT titer was strongly positive in vaccinated individuals and moderately positive in patients with COVID-19. No significant correlation was observed in vaccinated individuals infected with COVID-19. In patients infected with Alpha and Delta, the lowest VNT positivity rate was for the Omicron variant (85.0%/83.3%). Patients infected with the Alpha variant showed the lowest NT titer for the Omicron variant (median titer 32) compared to the Wuhan/Delta variants (64/128). Patients infected with the Delta variant had the lowest NT titer to the Omicron variant (median 32), compared to the Wuhan/Alpha variants (64/128). Patients infected with the Omicron variant showed similar titers to the Delta/Wuhan variants (128) and higher to the Alpha variant (256). Conclusions: The cross-immunity to SARS-CoV-2 is lowest for the Omicron variant compared to the Alpha/Delta variants.

show abstract

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Russo,

Mendes-Corrêa,

Lins

et al. 2023

Vaccines

View full text Add to dashboard Cite

Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.

show abstract

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant

Cited by 3 publications

References 23 publications

No detection of SARS-CoV-2 in domestic cats exposed to infected owners during the Omicron Wave in São Paulo, Brazil

No detection of SARS-CoV-2 in domestic cats exposed to infected owners during the Omicron Wave in São Paulo, Brazil

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Contact Info

Product

Resources

About